FINWIRES · TerminalLIVE
FINWIRES

ACMリサーチ、香港上場に向けた提案が最大1億ドルの資金援助を受ける

-- ACMリサーチ(ACMR)は、ケリスデール・キャピタル・マネジメントとスティームボート・キャピタル・パートナーズから、香港上場に向けた支援提案を受けました。両社は、それぞれ最低2,000万ドル、合計で最大1億ドルのアンカー投資を行う予定です。 水曜日にACMのCEOと取締役会宛てに送られた書簡の中で、両社は、香港上場によって、米国で取引されているACMRと、上海証券取引所に上場しているACMリサーチ(上海)の株式であるACMSとの間の評価額の差を縮めることができると述べています。 ケリスデールとスティームボートは、合わせて約60万株のACM株を保有または助言しており、香港上場と香港上場の株式との二重上場により、米国株主は香港上場株の評価額がより高いと判断した場合、保有株を香港上場株に転換できると述べています。 両社は、慣例的なロックアップ期間を受け入れる用意があり、ACMRの株価が上場前に上昇した場合、より高い評価額であっても参加する可能性があると述べています。彼らはまた、ACMが上海子会社の香港上場を目指す別の計画についても支持を表明した。 ACMはからのコメント要請にすぐには応じなかった。

Price: $52.73, Change: $+1.52, Percent Change: +2.97%

Related Articles

Asia

Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%

Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.

$ASX:ONE
Asia

Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low

Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.

$ASX:PAR
Asia

Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%

Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.

$SHA:600703